Akebia Therapeutics appointed Myles Wolf as a Class II director and selected Ernst & Young LLP as its independent public accounting firm.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Akebia Therapeutics appointed Myles Wolf as a Class II director and selected Ernst & Young LLP as its independent public accounting firm.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Akebia Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
- Ernst & Young LLP
Coverage
Newest first; wire copies grouped- Unknown outlet